Ruxolitinib (Jakavi, Vobrusta)
Ruxolitinib
Novartis South Africa (Pty) Ltd
Registration
- Applicant
- Novartis South Africa (Pty) Ltd
- Registrations
- 8
- Schedule source
- Consolidated Schedules 06 July 2026
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Jakavi 5 MG tablet EACH TABLET CONTAINS :RUXOLITINIB PHOSPHATE EQUIVALENT TO RUXOLIYINIB 5,0 mg | 5 mgTablet | 48010948/34/0109 | Registered | S4 | None |
| Jakavi 15 MG tablet EACH TABLET CONTAINS :RUXOLITINIB 15,0 mg | 15 mgTablet | 48011048/34/0110 | Registered | S4 | None |
| Jakavi 20 MG tablet EACH TABLET CONTAINS :RUXOLITINIB 20,0 mg | 20 mgTablet | 48011148/34/0111 | Registered | S4 | None |
| Vobrusta 5 MG EACH TABLET CONTAINS :RUXOLITINIB 5,0 mg | 5 mg | 48090048/34/0900 | Registered | S4 | None |
| Vobrusta 15 MG EACH TABLET CONTAINS :RUXOLITINIB 15,0 mg | 15 mg | 48090148/34/0901 | Registered | S4 | None |
| Vobrusta 20 MG EACH TABLET CONTAINS :RUXOLITINIB 20,0 mg | 20 mg | 48090248/34/0902 | Registered | S4 | None |
| Jakavi 10 MG Each Tablet contains: Ruxolitinib Phosphate equivalent to Ruxolitinib 10,0 mg | 10 mg | 52078152/34/0781 | Registered | S4 | None |
| Vobrusta 10 MG Each Tablet contains: Ruxolitinib Phosphate equivalent to Ruxolitinib 10,0 mg | 10 mg | 52078252/34/0782 | Registered | S4 | None |
Regulatory status
Where S4 sits on the scale
Prescription-only medicine.
Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Ruxolitinib phosphate equivalent to ruxolitinib
S4: Ruxolitinib
Consolidated Schedules 06 July 2026, line 7863
Pharmacological class: Complementary Medicines: Health Supplements (class 34)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
Drag to rotate. Structure from PubChem CID 25126798.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.